



## **Director Resignation and Appointment**

Melbourne, Australia, 1 March 2024 – InhaleRx Ltd (ASX: IRX), (**'IRX'** or **'the Company'**) an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, advises of the resignation of Dr John Crock as a director of the Company and the appointment of Mr James Barrie as a director of the Company. These changes are effective from 1 March 2024.

Dr Crock has informed the Board of his resignation due to a significant recent increase in time commitment related to his surgical practice. He has, however, agreed to continue to support the Company and will stay involved in an advisory capacity.

In the interim, whilst a new director is recruited, James Barrie, IRX's Company Secretary, has consented to act as a director. Mr Barrie is a professional Company Secretary and Director and brings considerable experience as a Director of several listed and unlisted pharmaceutical, bio-tech and med-tech companies.

The Board thanks Dr Crock for his contribution as a director since his appointment in 2022 and wishes him every success in his future endeavours. An Appendix 3Z for Dr Crock and Appendix 3X for Mr Barrie is attached to this announcement.

Authorised by the Board of Directors.

### **For further information:**

[www.inhalerx.com.au](http://www.inhalerx.com.au)

James Barrie, Company Secretary

Phone +61 3 8678 4091

### **About InhaleRx Limited (ASX: IRX) – [www.inhalerx.com.au](http://www.inhalerx.com.au)**

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration to treat Panic Disorder and pain using rapid and cost effective regulatory pathways, such as 505(b)(2). A 505(b)(2) application is a NDA that contains full reports of investigations of safety and effectiveness where at least some of the information required for approval comes from studies available in the public domain.

There is a significant economic opportunity for IRX and the Company's shareholders as these carefully selected medical indications under investigation currently have extremely limited treatment options, whilst also offering a low side effect profile.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.

InhaleRx Limited (ACN 611 845 820)  
Level 16  
414 La Trobe Street  
Melbourne VIC 3000  
Phone: +61 3 8678 4091

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity: INHALERX LIMITED</b>
<b>ACN: 611 845 820</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	JOHN CROCK
<b>Date of last notice</b>	27 SEPTEMBER 2022
<b>Date that director ceased to be director</b>	1 MARCH 2024

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
NIL

## Appendix 3Z

### Final Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest	Number & class of securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest</p> <p>J &amp; W CROCK SUPER PTY LTD &lt;J &amp; W CROCK SUPER FUND A/C&gt;</p> <p>JOHN CROCK IS A DIRECTOR OF THIS ENTITY</p>	1,082,092 ORDINARY SHARES

#### Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity: INHALERX LIMITED</b>
<b>ACN: 611 845 820</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	JAMES BARRIE
<b>Date of appointment</b>	1 MARCH 2024

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
NIL

## Appendix 3X

### Initial Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>Number &amp; class of Securities</b>
N/A	NIL

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	N/A

---

+ See chapter 19 for defined terms.